CN108948200A - A kind of anti-human CSF-1R monoclonal antibody and its application - Google Patents
A kind of anti-human CSF-1R monoclonal antibody and its application Download PDFInfo
- Publication number
- CN108948200A CN108948200A CN201810788630.8A CN201810788630A CN108948200A CN 108948200 A CN108948200 A CN 108948200A CN 201810788630 A CN201810788630 A CN 201810788630A CN 108948200 A CN108948200 A CN 108948200A
- Authority
- CN
- China
- Prior art keywords
- antibody
- seq
- cdr
- monoclonal antibody
- human csf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
The present invention relates to a kind of anti-human CSF-1R monoclonal antibody and its applications, while providing coding nucleic acid molecule, expression vector, host cell and the method for expressing the antibody of the antibody.Additionally provide antibody mediated immunity coupling conjugate, bispecific molecule, embedding and antigen receptor, pharmaceutical composition and purposes including antibody of the present invention.Compared with the existing technology, the invention has the following advantages that the monoclonal antibody of energy specific recognition people CSF-1R of the invention, affinity of the antibody in conjunction with people CSF-1R is better than existing anti-human CSF-1R monoclonal antibody, and combines unique epitope, and sequence is novel.
Description
Technical field
The present invention relates to a kind of high-affinity and with the monoclonal antibody or antibody piece of functional anti-human CSF1R
Section.Invention also provides the coding nucleic acid molecule of the antibody, expression vector, host cells and for expressing the antibody
Method.Additionally provide including antibody of the present invention antibody mediated immunity coupling conjugate, bispecific molecule, embedding and antigen receptor,
Pharmaceutical composition and diagnostic and therapeutic method.
Background technique
Colony-stimulating factor 1 receptor (CSF-1R) belongs to the receptor tyrosine kinase family of type III, by proto-oncogene c-
Fms coding, protein structure include kinase domain intracellular and the extracellular ligand knot by the similar structure composition of 5 immunoglobulins
Close area.CS1R is expressed on mononuclear phagocytic cells surface, is played a crucial role to the survival of mononuclear phagocytic cells, proliferation, differentiation
(Felix,et al.,(2015)Structure 23,1621-1631).And CSF1R is also high to express in kinds of tumor cells perhaps
Surface.For example, CSF1R expression and tumor tissues size and low survival are closely related.KLUGER,et al.(2004)Clinical
cancer research.vol.10,no.1,p.173-7;SCHOLL,et al.(1994)Journal of the
National Cancer Institute.vol.86, no.2, p.120-6.) is in oophoroma and carcinoma of endometrium, northern
Hybridization analysis shows that most tumor tissues co-express CSF1 and CSF1R, and normal endometrial tissue CSF1R expression is very
Weak (et al.(1991)Cancer,vol.67,no.4,p.990-6).It is huge that CSF1R is also expressed in tumor infiltrating
Phagocyte surface (CHAMBERS, et al. (1997) .Clinical Cancer Research.vol.3, no.6, p.999-
1007)。
After the extracellular region combination CSF-1 of CSF1R, cause CSF1R Receptor dimerization and its autophosphorylation intracellular, thus
Originate intracellular signal transmitting.Abnormal receptor tyrosine kinase III signal transmitting causes a large amount of inflammation diseases and cancer to mention
Show that RTK type III intracellular plays central role in congenital and the acquired immune response.For example, abnormal CSF1R signal transmitting
Typically occur in a variety of human diseases pathological states of such as rheumatoid arthritis, atherosclerosis and tumour growth.
(Chitu and Stanley,(2006),Curr.Opin.Immunol.18,39-48;Masteller and Wong,
(2014),Drug Discov.Today,19,1212-1216;Pollard(2009),Nat.Rev.Immunol.9,259-
270;Stanley and Chitu,(2014),Perspect.Biol.6,a021857;Verstraete and Savvides,
(2012),Nat.Rev.Cancer.12,753-766)。
CSF1R signal is also proved to play physiological action in bone remodeling.The animal of gene knockout CSF1 or CSF1R are usual
Show as osteopetrotic phenotype.For a long time, CSF1R inhibitor is as a kind of cancer, diseases associated with inflammation or bone loss disorders
Potential therapy is furtherd investigate.Pexidartinib, a kind of inhibitor of CSF1R are clinical in 3 phases for the treatment of giant cell tumor of tendon sheath
Powerful curative effect is shown in test.Another CSF1R inhibitor, Cabiralizumab, a kind of target tumor correlation macrophage
The monoclonal antibody of cell, the positive early studies in man for carrying out metastatic cancer of pancreas.Another kind is in the drug of clinic II phase
JNJ-40346527, a kind of oral CSF1R inhibitor, the mechanism of action are the survival of inhibition macrophage, proliferation and differentiation, but right
In the intractable active rheumatoid arthritis of disease repairing type antirheumatic drug (DMARD-refractory active
Rheumatoid arthritis) treatment is to no effect.
Although CSF1R antibody has exploitation, disease as above for treatment has more high-affinity and other drugs pass
The CSF1R inhibitor of keyness matter, especially monoclonal antibody need to be furtherd investigate exploitation.
Summary of the invention
In order to overcome drawbacks described above, the object of the present invention is to provide a kind of anti-human CSF-1R monoclonal antibody and its application,
The antibody has high-affinity and functionality, is better than existing anti-human CSF-1R monoclonal antibody.
In order to achieve the above object, the present invention provides a kind of anti-human CSF-1R monoclonal antibody, which is characterized in that the antibody
Include: heavy chain and light chain;
The heavy chain and light chain includes variable region, which includes complementary determining region;
Complementary determining region CDR1, CDR2 and CDR3 of the heavy chain are indicated with CDR-H1, CDR-H2 and CDR-H3 respectively;
Complementary determining region CDR1, CDR2 and CDR3 of the light chain are indicated with CDR-L1, CDR-L2 and CDR-L3 respectively;
The amino acid sequence of the CDR-H1 is shown in SEQ ID NO:3;
The amino acid sequence of the CDR-H2 is shown in SEQ ID NO:4;
The amino acid sequence of the CDR-H3 is shown in SEQ ID NO:5;
The amino acid sequence of the CDR-L1 is shown in SEQ ID NO:6;
The amino acid sequence of the CDR-L2 is shown in SEQ ID NO:7;
The amino acid sequence of the CDR-L3 is shown in SEQ ID NO:8.
Heavy chain variable amino acid sequence is shown in SEQ ID NO:1;Chain variable region amino acid sequence is SEQ ID
Shown in NO:2.
A kind of nucleic acid molecule, the nucleic acid molecule coding anti-human CSF-1R monoclonal antibody;
The sequence of the nucleic acid molecule is selected from SEQ ID NO:9 and/or SEQ ID NO:10;
The heavy chain variable region of the sequence SEQ ID NO:9 coding antibody;
The light chain variable region of the sequence SEQ ID NO:10 coding antibody.
A kind of expression vector, the expression vector contain the nucleic acid molecule.
A kind of host cell, the host cell contain the expression vector.
A kind of preparation method of anti-human CSF-1R monoclonal antibody, the preparation method comprise the following steps:
Step 1: the expression vector of nucleic acid molecule of the preparation containing the expression anti-human CSF-1R monoclonal antibody;
Step 2: transfecting eukaryotic host cell with the expression vector of step 1;
Step 3: the eukaryotic host cell that incubation step 2 transfects;
Step 4: isolating and purifying, obtain the antibody.
The invention further relates to the antibody mediated immunity coupling conjugates, double special for including anti-human CSF-1R monoclonal antibody above-mentioned
Property molecule, embedding and antigen receptor or pharmaceutical composition.
The invention further relates to anti-human CSF-1R monoclonal antibodies to prepare anti-tumor drug, rheumatoid arthritis drug, move
Application in pulse atherosclerosis drug or bone remodeling drug.
The heavy chain and light chain all further includes constant region, which is the constant region of human IgG, it is therefore preferable to IgG1's
Constant region.
Compared with the existing technology, the invention has the following advantages that the monoclonal of energy specific recognition people CSF-1R of the invention
Antibody, affinity of the antibody in conjunction with people CSF-1R are better than existing anti-human CSF-1R monoclonal antibody, and sequence is novel.
Specific embodiment
The following further describes the technical solution of the present invention with reference to embodiments.
One, the acquisition of antibody
Embodiment 1 obtains the mouse monoclonal antibody of the anti-CSF1R of specificity by fusion hybridoma technology
1.1 animal immune
According to (E Harlow, D.Lane, Antibody:A Laboratory Manual, Cold Spring in document
Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1998) mouse is immunized in general method.It is immune
It originally was recombined human CSF1R (amino acid section I le20-Glu 512) albumen (Acro that C-terminal contains human IgG1's Fc label
biosystems,Cat#CSR-H5258).Albumen (Acro biosystems, cat# using recombined human CSF1R with his label
CSR-H5228) the detection antigen as measurement serum titer and hybridoma screening.Briefly, suitable freund adjuvant is taken out to arrive
In 1.5ml EP pipe, oscillator is mixed.Antigen protein solution is prepared with PBS.Amount mixes adjuvant as required and proteantigen is molten
Liquid mutually pushes away the solution that fully emulsified antigen forms stable Water-In-Oil by syringe, then carries out animal injection.It is imitated according to serum
Valence measurement result usually requires after first immunisation to can be only achieved good immune effect after carrying out 2 to 3 booster immunizations.Selection
The high immune mouse row intraperitoneal injection of serum titer carries out cell fusion after exempting from eventually.
1.2 hybridoma fusions and screening
Before cell fusion, culture murine myeloma cell (SP2/0-Ag14, ATCC#CRL-1581) is in logarithmic growth
Phase.It puts to death immunized mice gnotobasis and takes spleen, PEGylated fusion spleen bone-marrow-derived lymphocyte and SP2/0 are used according to method in document
Myeloma cell (E Harlow, D.Lane, Antibody:A Laboratory Manual, (Cold Spring Harbor
Laboratory Press,Cold Spring Harbor,N.Y.,1998);Kohler G,and Milstein C,"
Continuous cultures of fused cell secreting antibody of predefined
specificity,"Nature,256:495-497(1975)).Fused 96 porocyte culture plates of plating cells, usual 7 arrive
The Growth of Hybridoma Cell that survival can be observed after 10 days under microscope comes out.Plating cells after two weeks, are collected in each hole culture
Clearly, hybridoma screening is carried out with ELISA method employment CSF1R-his proteantigen.It is summarized as follows, with the people of 60ul 2ug/ml
The PBS solution coated elisa plate of CSF1R-his antigen, 4 degree (" degree " of the invention refer to degree Celsius) overnight.Then PBST board-washing 4
After secondary, the PBST solution for 5% skimmed milk power that 200 holes μ l/ are added is placed in 37 degree and closes 2 hours.60 μ l/ are added in board-washing again
The hybridoma supematant in hole, 37 degree are incubated for 40 minutes, then board-washing 4 times.Diluted horseradish peroxidase is added with 100 holes μ l/
The sheep anti-Mouse secondary antibody (Jackson Immuno research, cat#115-036-071) of label, 37 degree are incubated for 40 minutes, and
Board-washing 4 times afterwards, pat dry.The TMB chromogenic substrate in 100 holes μ l/ is added, color development at room temperature 5 to 15 minutes, then uses the sulfuric acid solution of 1M
It terminates, measures the light absorption value in each hole of 450 nanometers.Choose the positive hybridoma holes cell of ELISA colour developing, is transferred to 24 orifice plates
In, continue to cultivate.And the second wheel secondary screening is carried out by ELISA method, it filters out specific recognition CSF1R antigen and can block
The hybridoma that CSF1R/CSF1 is combined (the results are shown in Table 1, wherein 2E10 is the hybridoma that the present invention obtains, and hybridoma expression is originally
The obtained anti-human CSF-1R monoclonal antibody of invention), it is subcloned by limiting dilution assay, obtains desired monoclonal cell strain.
Then by these monoclonal antibodies of a small amount of Expression products of free serum culture, antibody purification carries out the Function Appraising point of next step
Analysis.
The ELISA of 1 CSF1R Mouse Hybridoma Cells supernatant of table tests and assesses
Two, ira vitro analytical methods
Embodiment 2 is used to measure the ira vitro analytical methods of CSF1R monoclonal antibody functional activity
2.1 binding abilities based on capture ELSIA measurement antibody
Special secondary antibody (Jackson the Immuno Research, #115- of goat anti-mouse igg Fcr is prepared with 1xPBS
006-071), make its final concentration of 2 μ g/ml, with 100 μ l/ hole liquid feedings in 96 hole elisa Plates, 4 degree of coatings are overnight.Next day, with containing
After PBS solution (i.e. the 1xPBST) board-washing 4 times of 0.05% polysorbas20, the PBST that 5% skimmed milk power in 200 holes μ l/ is added is molten
Liquid is placed in 37 degree and closes 2 hours.Board-washing again, after the dilution antibody-solutions or hybridoma supematant in 100 holes μ l/ are added, 37 degree are incubated
It educates 40 minutes, then board-washing 4 times.With 100 holes μ l/ be added prepare 60nM biotin labeling people CSF1R Fc protein solution (
In the PBST of 2.5% skimmed milk power), 37 degree are incubated for 40 minutes, then board-washing 4 times.It is diluted that 1:10000 is added with 100 holes μ l/
The Streptavidin (Jackson Immuno Research, #016-030-084) of horseradish peroxidase-labeled, 37 degree of incubations
40 minutes, then board-washing 4 times, patted dry.Add the ELISA chromogenic substrate TMB in 100 holes μ l/, color development at room temperature 5 to 15 minutes, then
With the sulfuric acid solution color development stopping of 1M, the light absorption value in each hole of 450 nanometers is measured.
The binding ability of 2.2 flow cytometries assessment antibody combination cell film surface CSF1R antigen
The 293F cell line that the film surface in logarithmic growth phase is overexpressed people CSF1R is collected, after washing cell 2 times with PBS
Cell is resuspended with FACS buffer solution (PBS solution containing 2% fetal calf serum).Density is adjusted, is plated on 2x105 cells/well
In 96 hole U bottom plates, 300g is centrifuged 5 minutes, and incline supernatant, is added the CSF1R antibody-solutions of gradient dilution and is placed on ice
It is incubated for 40 minutes.It washes cell 2 times, adds the sheep anti-Mouse secondary antibody (Jackson of 100 hole μ L/ phycoerythrin fluorescent markers
Immunoresearch, Cat#115-116-072,1:1000 dilution), 4 degree are protected from light and are incubated for after forty minutes, wash cell 3 times, then
Every hole adds the FACS buffer solution of 100 μ L to be resuspended, and blows upper machine testing after even cell.Use BD company Canto II model fluidic cell
Instrument measures the fluorescence intensity of every hole cell.Data processing is carried out using Graphpad prism software, obtains antibody combination cell
EC50 concentration value (reaching corresponding antibody concentration value when the antibody maximum fluorescence binding signal 50%).
2.3 competitive ELISA
2.3.1 ligand receptor, which combines, blocks ELISA
The blocking ability that CSF1R/CSF1 is combined by competitive ELISA method assessment CSF1R antibody.It is summarized as follows, uses
1xPBS prepares the CSF1-his albumen (BSI, cat#BS-TA1601154-96) of people, makes its final concentration of 2 μ g/ml, with 100 μ
The hole l/ liquid feeding is in 96 hole elisa Plates, and 4 degree of coatings are overnight.Next day, with PBS solution (i.e. PBST) board-washing of the polysorbas20 containing 0.05%
After 4 times, the PBST solution for 5% skimmed milk power that 200 holes μ l/ are added is placed in 37 degree and closes 2 hours.Board-washing 4 times again.
CSF1R antibody or control antibodies gradient dilution in people's CSF1R FC protein solution containing biotin labeling,
Rear room temperature is prepared to incubate in advance 40 minutes.Then the solution of the antibody and CSF1R Fc biotin that have been incubated for is added to 100 holes μ l/
It has been coated on the plate of CSF1-his, 37 degree are incubated for board-washing 4 times again after forty minutes.Horseradish peroxide then is added with 100 holes μ l/
The Streptavidin of compound enzyme label, 37 degree of incubation board-washing 4 times after forty minutes pat dry.Add the TMB colour developing and 50 in 100 holes μ l/
The 1M sulfuric acid in the hole μ l/ terminates reaction, measures the absorption value of 450 nanometers.It is carried out at data using Graphpad prism software
Reason obtains the IC50 concentration value that antibody blocking CSF1R/CSF1 is combined.
2.3.2 reference antibody blocks ELISA
Pass through competitive ELISA method assessment CSF1R antibody blocking reference antibody/CSF1R antigen binding blocking ability.Letter
State it is as follows, with 1xPBS prepare reference antibody (cabiralizumab), make its final concentration of 1 μ g/ml, with 100 μ l/ hole liquid feedings in
96 hole elisa Plates, 4 degree of coatings are overnight.Next day is added after PBS solution (i.e. PBST) board-washing 4 times containing 0.05% polysorbas20
The PBST solution of 5% skimmed milk power in 200 holes μ l/ is placed in 37 degree and closes 2 hours, board-washing 4 times again.
CSF1R antibody or control antibodies gradient dilution in people's CSF1R FC protein solution containing biotin labeling
In (10nM), prepares rear room temperature and incubate in advance 40 minutes.Then the solution for the antibody and CSF1R Fc biotin being incubated for 100 μ
The hole l/ is added on the plate for being coated with reference antibody, and 37 degree are incubated for board-washing 4 times again after forty minutes.Then with the addition of 100 holes μ l/
The Streptavidin of horseradish peroxidase-labeled, 37 degree of incubation board-washing 4 times after forty minutes, pats dry.Add TMB colour developing and 1M sulphur
Acid solution terminates reaction, measures the absorption value of 450 nanometers.Data processing is carried out using Graphpad prism software, is obtained
The IC50 concentration value that antibody blocking reference antibody/CSF1R is combined.
The combination activity of the anti-CSF1R mouse monoclonal antibody of embodiment 3
According to analysis method described in embodiment 2, the combination Activity Summary such as the following table 2 for CSF1R antibody of testing and assessing.Wherein
Benchmark (Cabiralizumab) is existing not commercialized anti-human CSF1R monoclonal antibody as control.From table 2
It is found that the combination activity of anti-human CSF-1R monoclonal antibody and people's CSF1R antigen of the invention is substantially better than Benchmark.
Table 2 purifies the combination activity of CSF1R mouse monoclonal antibody
4 functional blockade of embodiment experiment (analysis method referring to 2.3), it is real to obtain the antibody functional based on ELISA
Data are commented in test
Such as the following table 3, the functional evaluating result of anti-CSF1R mouse monoclonal antibody is summarized.
Table 3 purifies the functional assessment of CSF1R mouse monoclonal antibody
The competitive ELISA experiment of antibody on human CSF1/CSF1R shows that 2E10 antibody of the invention can specific blockage in table 3
CSF1R combines its ligand CSF1, and blocking ability is substantially better than Benchmark;Antibody is to benchmark/ simultaneously
The competitive ELISA experiment of humanCSF1R shows that 2E10 antibody does not block BM combination people's CSF1R antigen, shows what 2E10 was combined
Epitope is different from Benchmark antibody, is unique epitope.
Embodiment 5DNA clone and sequencing, the variable region protein sequencing of anti-CSF1R mouse monoclonal antibody
Using Trizol reagent (Invitrogen, catalog#15596-018) from the mouse monoclonal cell strain of culture
Middle extraction total serum IgE.Process is summarized as follows, the cell of 5x106 is collected by centrifugation into 1.5ml centrifuge tube, blots supernatant.Add 1ml
Trizol reagent and blow and beat repeatedly and be placed at room temperature for 5 minutes afterwards for several times for lytic cell.And then, every pipe is added 0.2ml's
Chloroformic solution, acutely concussion was placed at room temperature for 3 minutes after 15 seconds.Then, 4 degree of 12000g of centrifuge tube are centrifuged 10 minutes, take out centrifugation
Pipe draws upper strata aqueous phase solution into new 1.5ml centrifuge tube, adds the isopropanol of 0.4ml for precipitating from water phase
RNA.After mixing EP is managed and placed room temperature 10min manually, 4 degree of 12000g are centrifuged 10 minutes, abandon supernatant.The second of 1ml 75% is added
Alcohol, 4 degree of 7500rpm are centrifuged 5min again, abandon supernatant.Tube bottom RNA precipitate after ten minutes, is added 30 and arrives 50ul's in drying at room temperature
Sterile DEPC processing water dissolves RNA sample.
And then, selecting the reverse transcription cDNA kit (catalog#6110A) of Taraka becomes CDNA total serum IgE.It is real
The system of testing is formulated as follows, and+8.5 μ l RNase-free water (total 14ul) of+0.5 μ l Oligo (dT) of total serum IgE of 5 μ l is first placed in 65
5min initial denaturation is spent, is then put 2 minutes on ice.Further it is added+0.5 μ l's of dNTP mixture of+1 μ l of 5x buffer of 4 μ l
+ 1 μ l reverse transcriptase (20.5ul system in total) of RNase inhibitor, mixes after preparing, and runs 40 degree 50 minutes using PCR instrument, and 70
10min is spent, cDNA synthesis is completed.
CDNA is further formulated as follows at 3 ' ends plus Poly G, reaction system: the ddH2O of+33.5 μ l of cDNA sample of 5 μ l
Terminal deoxynucleotidyl transferase (the total volume of the dGTP+0.5 μ l of the CoCl2+1 μ l of+5 μ l of 10xTdT buffer of+5 μ l
50ul), it is mixed after preparing, runs 37 degree 30 minutes, 70 degree of 10min using PCR instrument, complete Poly G tailing.
Further, the gene magnification of antibody variable region is carried out using the cDNA of tailing as template.It can for amplification heavy chain of antibody
Become region sequence, prepare PCR reaction system: the general 0.5 μ l+ of poly C primer (forward primer) of 5 μ l+ of 10x Taq enzyme buffer is small
0.5 μ l+dNTP of mouse IgG1 reverse primer, 11 μ l+ddH2O of μ l+Taq 1 μ l+cDNA of polymerase, 41 μ l.It is light for amplification antibody
Chain variable region sequence prepares PCR reaction system: the general 0.5 μ l of poly C primer (forward primer) of 5 μ l+ of 10x Taq enzyme buffer
0.5 μ l+dNTP of+mouse IgG kappa reverse primer, 11 μ l+ddH2O of μ l+Taq polymerase 1ul+cDNA, 41 μ l.Antibody
The temperature cycles of heavy chain and light chain variable region PCR amplification are following (wherein step 2 to 4 repeats 25 circulations):
95 DEG C of .5min. of 1- initial denaturation
2- is denaturalized 95 DEG C of .20sec.
56 DEG C of .20sec. of 3- annealing
4- extends 72 DEG C of .30sec.
5- saves 25 DEG C of .60min.
PCR product is analyzed through 1% agarose gel electrophoresis, cut out corresponding size DNA section band (the about 600bp of VH,
Vkappa light chain about 500bp), the extracting of DNA is carried out with the gel DNA QIAquick Gel Extraction Kit (catalog#28704) of Qiagen.Letter
State as follows: gel weighing adds the QG buffer of 3 times of gel volumes, is then incubated for 10 minutes until gel is completely dissolved for 50 degree.Add
After the isopropanol mixing for entering 1 times of colloid product, sample moves to QIA purification column, is centrifuged 13000rpm 1 minute.The PE of 750ul is added
Buffer is into column, and then 13000rpm is centrifuged 1 minute.And 13000rpm is centrifuged liquid residual in 1 minute removal column again.Add
The water elution column for entering 30ul is centrifuged 1 minute, obtains the DNA sample of preparation, and the PCR product of purifying obtains the variable of antibody through sequencing
Region sequence is as shown in table 4, and the amino acid full length sequence of CSF1R mouse monoclonal antibody is as shown in table 5, CSF1R mouse monoclonal
The nucleotide sequence of antibody is as shown in table 6.
The variable region amino acid sequence and CDR region of 4 CSF1R mouse monoclonal antibody of table
The amino acid full length sequence of 5 CSF1R mouse monoclonal antibody of table
The DNA encoding sequence of 6 CSF1R mouse monoclonal antibody of table
In conclusion the monoclonal antibody of energy specific recognition people CSF-1R of the invention, the antibody is in conjunction with people CSF-1R
Affinity it is strong, sequence is novel, in conjunction with unique epitope.
It is discussed in detail although the contents of the present invention have passed through above preferred embodiment, but it should be appreciated that above-mentioned
Description is not considered as limitation of the present invention.After those skilled in the art have read above content, for of the invention
A variety of modifications and substitutions all will be apparent.Therefore, protection scope of the present invention should be limited to the appended claims.
Sequence table
<110>letter biotechnology (Nanjing) Co., Ltd difficult to understand is won
<120>a kind of anti-human CSF-1R monoclonal antibody and its application
<130> xhx2018071806
<141> 2018-07-18
<160> 14
<170> SIPOSequenceListing 1.0
<210> 1
<211> 121
<212> PRT
<213> Mus musculus
<400> 1
Asp Val Gln Leu Val Asp Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15
Ser Arg Lys Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Phe
20 25 30
Gly Met His Trp Val Arg Gln Ala Pro Glu Lys Gly Leu Glu Trp Val
35 40 45
Ala Tyr Ile Ser Ser Gly Ser Asn Thr Ile Tyr Tyr Ala Asp Thr Val
50 55 60
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Pro Lys Asn Thr Leu Phe
65 70 75 80
Leu Gln Met Thr Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr Cys
85 90 95
Ala Arg Trp Tyr Gly Asn Tyr Asn Tyr Tyr Ala Met Asp Tyr Trp Gly
100 105 110
Gln Gly Thr Ser Val Thr Val Ser Ser
115 120
<210> 2
<211> 107
<212> PRT
<213> Mus musculus
<400> 2
Asp Ile Gln Met Thr Gln Ser Pro Ala Ser Leu Ser Ala Ser Val Gly
1 5 10 15
Glu Thr Val Thr Ile Thr Cys Gly Ala Ser Glu Asn Ile Tyr Gly Thr
20 25 30
Leu Asn Trp Tyr Gln Arg Lys Gln Gly Lys Ser Pro Gln Leu Leu Ile
35 40 45
Tyr Gly Ala Thr Asn Leu Ala Asp Gly Leu Ser Ser Arg Phe Ser Gly
50 55 60
Ser Gly Ser Gly Arg Gln Tyr Ser Leu Lys Ile Ser Ser Leu His Pro
65 70 75 80
Asp Asp Ile Ala Thr Tyr Tyr Cys Gln Asn Val Leu Gly Ile Pro Phe
85 90 95
Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105
<210> 3
<211> 8
<212> PRT
<213> Mus musculus
<400> 3
Gly Phe Thr Phe Ser Ser Phe Gly
1 5
<210> 4
<211> 8
<212> PRT
<213> Mus musculus
<400> 4
Ile Ser Ser Gly Ser Asn Thr Ile
1 5
<210> 5
<211> 14
<212> PRT
<213> Mus musculus
<400> 5
Ala Arg Trp Tyr Gly Asn Tyr Asn Tyr Tyr Ala Met Asp Tyr
1 5 10
<210> 6
<211> 11
<212> PRT
<213> Mus musculus
<400> 6
Gly Ala Ser Glu Asn Ile Tyr Gly Thr Leu Asn
1 5 10
<210> 7
<211> 7
<212> PRT
<213> Mus musculus
<400> 7
Gly Ala Thr Asn Leu Ala Asp
1 5
<210> 8
<211> 9
<212> PRT
<213> Mus musculus
<400> 8
Gln Asn Val Leu Gly Ile Pro Phe Thr
1 5
<210> 9
<211> 363
<212> DNA
<213> Mus musculus
<400> 9
gatgtgcagc tggtggactc tgggggaggc ttagtgcagc ctggagggtc ccggaaactc 60
tcctgtgcag cctctggatt cactttcagt agctttggaa tgcactgggt tcgtcaggct 120
ccagagaagg ggctggagtg ggtcgcatac attagtagtg gcagtaatac catctactat 180
gcagacacag tgaagggccg attcaccatc tccagagaca atcccaagaa caccctgttc 240
ctgcaaatga ccagtctaag gtctgaggac acggccattt attactgtgc aagatggtat 300
ggtaactaca attactatgc tatggactac tggggtcaag gaacctcagt caccgtctcc 360
tca 363
<210> 10
<211> 321
<212> DNA
<213> Mus musculus
<400> 10
gacatccaga tgacccagtc tccagcttca ctgtctgcat ctgtgggaga aactgtcacc 60
atcacatgtg gagcaagtga gaatatttac ggtactttaa attggtatca gcggaaacag 120
ggaaaatctc ctcagctcct gatctatggt gcaaccaact tggcagatgg cctgtcatcg 180
aggttcagtg gcagtggatc tggtagacag tattctctca agatcagtag cctgcatcct 240
gacgatattg caacgtatta ctgtcaaaat gtgttaggta ttccattcac gttcggctcg 300
gggacaaagt tggaaataaa a 321
<210> 11
<211> 993
<212> DNA
<213> Mus musculus
<400> 11
gccaaaacaa cagccccatc ggtctatcca ctggcccctg tgtgtggaga tacaactggc 60
tcctcggtga ctctaggatg cctggtcaag ggttatttcc ctgagccagt gaccttgacc 120
tggaactctg gatccctgtc cagtggtgtg cacaccttcc cagctgtcct gcagtctgac 180
ctctacaccc tcagcagctc agtgactgta acctcgagca cctggcccag ccagtccatc 240
acctgcaatg tggcccaccc ggcaagcagc accaaggtgg acaagaaaat tgagcccaga 300
gggcccacaa tcaagccctg tcctccatgc aaatgcccag cacctaacct cttgggtgga 360
ccatccgtct tcatcttccc tccaaagatc aaggatgtac tcatgatctc cctgagcccc 420
atagtcacat gtgtggtggt ggatgtgagc gaggatgacc cagatgtcca gatcagctgg 480
tttgtgaaca acgtggaagt acacacagct cagacacaaa cccatagaga ggattacaac 540
agtactctcc gggtggtcag tgccctcccc atccagcacc aggactggat gagtggcaag 600
gagttcaaat gcaaggtcaa caacaaagac ctcccagcgc ccatcgagag aaccatctca 660
aaacccaaag ggtcagtaag agctccacag gtatatgtct tgcctccacc agaagaagag 720
atgactaaga aacaggtcac tctgacctgc atggtcacag acttcatgcc tgaagacatt 780
tacgtggagt ggaccaacaa cgggaaaaca gagctaaact acaagaacac tgaaccagtc 840
ctggactctg atggttctta cttcatgtac agcaagctga gagtggaaaa gaagaactgg 900
gtggaaagaa atagctactc ctgttcagtg gtccacgagg gtctgcacaa tcaccacacg 960
actaagagct tctcccggac tccgggtaaa tga 993
<210> 12
<211> 321
<212> DNA
<213> Mus musculus
<400> 12
cgggctgatg ctgcaccaac tgtatccatc ttcccaccat ccagtgagca gttaacatct 60
ggaggtgcct cagtcgtgtg cttcttgaac aacttctacc ccaaagacat caatgtcaag 120
tggaagattg atggcagtga acgacaaaat ggcgtcctga acagttggac tgatcaggac 180
agcaaagaca gcacctacag catgagcagc accctcacgt tgactaagga cgagtatgaa 240
cgacataaca gctatacctg tgaggccact cacaagacat caacttcacc cattgtcaag 300
agcttcaaca ggggagagtg t 321
<210> 13
<211> 330
<212> PRT
<213> Mus musculus
<400> 13
Ala Lys Thr Thr Ala Pro Ser Val Tyr Pro Leu Ala Pro Val Cys Gly
1 5 10 15
Asp Thr Thr Gly Ser Ser Val Thr Leu Gly Cys Leu Val Lys Gly Tyr
20 25 30
Phe Pro Glu Pro Val Thr Leu Thr Trp Asn Ser Gly Ser Leu Ser Ser
35 40 45
Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Asp Leu Tyr Thr Leu
50 55 60
Ser Ser Ser Val Thr Val Thr Ser Ser Thr Trp Pro Ser Gln Ser Ile
65 70 75 80
Thr Cys Asn Val Ala His Pro Ala Ser Ser Thr Lys Val Asp Lys Lys
85 90 95
Ile Glu Pro Arg Gly Pro Thr Ile Lys Pro Cys Pro Pro Cys Lys Cys
100 105 110
Pro Ala Pro Asn Leu Leu Gly Gly Pro Ser Val Phe Ile Phe Pro Pro
115 120 125
Lys Ile Lys Asp Val Leu Met Ile Ser Leu Ser Pro Ile Val Thr Cys
130 135 140
Val Val Val Asp Val Ser Glu Asp Asp Pro Asp Val Gln Ile Ser Trp
145 150 155 160
Phe Val Asn Asn Val Glu Val His Thr Ala Gln Thr Gln Thr His Arg
165 170 175
Glu Asp Tyr Asn Ser Thr Leu Arg Val Val Ser Ala Leu Pro Ile Gln
180 185 190
His Gln Asp Trp Met Ser Gly Lys Glu Phe Lys Cys Lys Val Asn Asn
195 200 205
Lys Asp Leu Pro Ala Pro Ile Glu Arg Thr Ile Ser Lys Pro Lys Gly
210 215 220
Ser Val Arg Ala Pro Gln Val Tyr Val Leu Pro Pro Pro Glu Glu Glu
225 230 235 240
Met Thr Lys Lys Gln Val Thr Leu Thr Cys Met Val Thr Asp Phe Met
245 250 255
Pro Glu Asp Ile Tyr Val Glu Trp Thr Asn Asn Gly Lys Thr Glu Leu
260 265 270
Asn Tyr Lys Asn Thr Glu Pro Val Leu Asp Ser Asp Gly Ser Tyr Phe
275 280 285
Met Tyr Ser Lys Leu Arg Val Glu Lys Lys Asn Trp Val Glu Arg Asn
290 295 300
Ser Tyr Ser Cys Ser Val Val His Glu Gly Leu His Asn His His Thr
305 310 315 320
Thr Lys Ser Phe Ser Arg Thr Pro Gly Lys
325 330
<210> 14
<211> 107
<212> PRT
<213> Mus musculus
<400> 14
Arg Ala Asp Ala Ala Pro Thr Val Ser Ile Phe Pro Pro Ser Ser Glu
1 5 10 15
Gln Leu Thr Ser Gly Gly Ala Ser Val Val Cys Phe Leu Asn Asn Phe
20 25 30
Tyr Pro Lys Asp Ile Asn Val Lys Trp Lys Ile Asp Gly Ser Glu Arg
35 40 45
Gln Asn Gly Val Leu Asn Ser Trp Thr Asp Gln Asp Ser Lys Asp Ser
50 55 60
Thr Tyr Ser Met Ser Ser Thr Leu Thr Leu Thr Lys Asp Glu Tyr Glu
65 70 75 80
Arg His Asn Ser Tyr Thr Cys Glu Ala Thr His Lys Thr Ser Thr Ser
85 90 95
Pro Ile Val Lys Ser Phe Asn Arg Gly Glu Cys
100 105
Claims (9)
1. a kind of anti-human CSF-1R monoclonal antibody, which is characterized in that the antibody includes: heavy chain and light chain;
The heavy chain and light chain includes variable region, which includes complementary determining region;
Complementary determining region CDR1, CDR2 and CDR3 of the heavy chain are indicated with CDR-H1, CDR-H2 and CDR-H3 respectively;
Complementary determining region CDR1, CDR2 and CDR3 of the light chain are indicated with CDR-L1, CDR-L2 and CDR-L3 respectively;
The amino acid sequence of the CDR-H1 is shown in SEQ ID NO:3;
The amino acid sequence of the CDR-H2 is shown in SEQ ID NO:4;
The amino acid sequence of the CDR-H3 is shown in SEQ ID NO:5;
The amino acid sequence of the CDR-L1 is shown in SEQ ID NO:6;
The amino acid sequence of the CDR-L2 is shown in SEQ ID NO:7;
The amino acid sequence of the CDR-L3 is shown in SEQ ID NO:8.
2. a kind of anti-human CSF-1R monoclonal antibody according to claim 1, which is characterized in that heavy chain variable amino acid
Sequence is shown in SEQ ID NO:1;Chain variable region amino acid sequence is SEQ ID NO:
Shown in 2.
3. a kind of nucleic acid molecule, which is characterized in that the nucleic acid molecule encodes anti-human CSF- as claimed in claim 1 or 2
1R monoclonal antibody;
The sequence of the nucleic acid molecule is selected from SEQ ID NO:9 and/or SEQ ID NO:10;
The heavy chain variable region of the sequence SEQ ID NO:9 coding antibody;
The light chain variable region of the sequence SEQ ID NO:10 coding antibody.
4. a kind of expression vector, which is characterized in that the expression vector contains nucleic acid molecule as claimed in claim 3.
5. a kind of host cell, which is characterized in that the host cell contains expression vector as claimed in claim 4.
6. a kind of preparation method of anti-human CSF-1R monoclonal antibody of any of claims 1 or 2, which is characterized in that the preparation
Method comprises the following steps:
Step 1: the expression vector of nucleic acid molecule of the preparation containing the expression anti-human CSF-1R monoclonal antibody;
Step 2: transfecting eukaryotic host cell with the expression vector of step 1;
Step 3: the eukaryotic host cell that incubation step 2 transfects;
Step 4: isolating and purifying, obtain the antibody.
7. the preparation method of anti-human CSF-1R monoclonal antibody according to claim 6, which is characterized in that the expression
Carrier contains the nucleotide sequence selected from SEQ ID NO:9 and/or SEQ ID NO:10.
8. including antibody mediated immunity the coupling conjugate, bispecific of anti-human CSF-1R monoclonal antibody of any of claims 1 or 2
Molecule, embedding and antigen receptor or pharmaceutical composition.
9. anti-human CSF-1R monoclonal antibody of any of claims 1 or 2 is preparing anti-tumor drug, rheumatoid arthritis medicine
Application in object, atherosclerosis drug or bone remodeling drug.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810788630.8A CN108948200B (en) | 2018-07-18 | 2018-07-18 | A kind of anti-human CSF-1R monoclonal antibody and its application |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810788630.8A CN108948200B (en) | 2018-07-18 | 2018-07-18 | A kind of anti-human CSF-1R monoclonal antibody and its application |
Publications (2)
Publication Number | Publication Date |
---|---|
CN108948200A true CN108948200A (en) | 2018-12-07 |
CN108948200B CN108948200B (en) | 2019-05-10 |
Family
ID=64496286
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810788630.8A Active CN108948200B (en) | 2018-07-18 | 2018-07-18 | A kind of anti-human CSF-1R monoclonal antibody and its application |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108948200B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114426580A (en) * | 2022-04-07 | 2022-05-03 | 北京科诺信诚科技有限公司 | anti-CSF-1R antibodies, products, methods and uses thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102834414A (en) * | 2010-04-01 | 2012-12-19 | 伊姆克罗尼责任有限公司 | Antibodies against csf-1r |
-
2018
- 2018-07-18 CN CN201810788630.8A patent/CN108948200B/en active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102834414A (en) * | 2010-04-01 | 2012-12-19 | 伊姆克罗尼责任有限公司 | Antibodies against csf-1r |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114426580A (en) * | 2022-04-07 | 2022-05-03 | 北京科诺信诚科技有限公司 | anti-CSF-1R antibodies, products, methods and uses thereof |
CN114426580B (en) * | 2022-04-07 | 2022-06-24 | 北京科诺信诚科技有限公司 | anti-CSF-1R antibodies, products, methods and uses thereof |
Also Published As
Publication number | Publication date |
---|---|
CN108948200B (en) | 2019-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107921127B (en) | T cell receptor-like antibodies specific for PRAME peptides | |
CA2367901C (en) | Monoclonal antibodies, antigens and diagnosis and therapy of malignant diseases | |
DK2888283T3 (en) | ANTIBODIES AND VACCINES FOR TREATING ROR1 CANCER AND INHIBITIVE METASTASE | |
CN110381998B (en) | anti-LAIR 1 antibodies and uses thereof | |
KR20130038278A (en) | Anti-human trop-2 antibody having antitumor activity in vivo | |
CN111995682B (en) | Anti-human SIRP alpha monoclonal antibody and application thereof | |
US20100151503A1 (en) | Method of detecting liver cancer, diagnostic for liver cancer and remedy for cancer | |
CN108948201B (en) | Anti-human CSF-1R monoclonal antibody and application | |
KR20200022479A (en) | Chimeric Antibodies for the Treatment of Amyloid Deposition Disease | |
CN112010979A (en) | Anti-human SIRP alpha monoclonal antibody and application thereof | |
CN109096397B (en) | A kind of anti-human CSF-1R monoclonal antibody and application | |
CN109053887B (en) | A kind of anti-human CSF-1R monoclonal antibody and purposes | |
TWI809426B (en) | Anti-claudin18.2 antibody and the use thereof | |
CN108948200B (en) | A kind of anti-human CSF-1R monoclonal antibody and its application | |
CN108948198A (en) | Anti-human CSF-1R monoclonal antibody and its application | |
CN109053889B (en) | A kind of anti-human PD1 monoclonal antibody and purposes | |
CN108948199B (en) | Anti-human CSF-1R monoclonal antibody and application thereof | |
CN108948202A (en) | A kind of anti-human PD1 monoclonal antibody and application thereof | |
CN109053888A (en) | A kind of anti-human CSF-1R monoclonal antibody and application thereof | |
WO2021175191A1 (en) | Anti-tim-3 antibody and use thereof | |
CN109053886A (en) | Anti-human CSF-1R monoclonal antibody and purposes | |
CN115703834A (en) | Anti-human CD47 monoclonal antibody and preparation method and application thereof | |
CN115703833A (en) | Monoclonal antibody with strong tumor cell phagocytosis promoting effect and application thereof | |
CN115746133A (en) | Anti-human CD47 monoclonal antibody and application thereof | |
CN116262787A (en) | Anti-human LAG-3 monoclonal antibody, and preparation method and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |